Short Interest in Halozyme Therapeutics, Inc. (NASDAQ:HALO) Expands By 8.1%

Halozyme Therapeutics, Inc. (NASDAQ:HALO) was the target of a large growth in short interest in December. As of December 31st, there was short interest totalling 9,500,000 shares, a growth of 8.1% from the December 15th total of 8,790,000 shares. Based on an average daily trading volume, of 1,670,000 shares, the short-interest ratio is presently 5.7 days. Currently, 7.6% of the company’s stock are sold short.

Halozyme Therapeutics Trading Down 1.0 %

Shares of Halozyme Therapeutics stock opened at $54.80 on Monday. The company has a current ratio of 10.36, a quick ratio of 9.15 and a debt-to-equity ratio of 3.32. Halozyme Therapeutics has a twelve month low of $33.15 and a twelve month high of $65.53. The firm has a market capitalization of $6.97 billion, a PE ratio of 18.15, a P/E/G ratio of 0.40 and a beta of 1.24. The firm’s 50-day moving average price is $49.62 and its 200 day moving average price is $54.12.

Analyst Ratings Changes

HALO has been the subject of several research reports. JMP Securities lifted their price objective on shares of Halozyme Therapeutics from $72.00 to $73.00 and gave the company a “market outperform” rating in a research note on Friday, November 1st. Cowen reiterated a “buy” rating on shares of Halozyme Therapeutics in a research note on Friday, October 18th. HC Wainwright lifted their price objective on shares of Halozyme Therapeutics from $68.00 to $70.00 and gave the company a “buy” rating in a report on Friday, January 10th. Piper Sandler increased their target price on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a “neutral” rating in a research note on Friday, January 10th. Finally, Wells Fargo & Company cut their price target on Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating for the company in a research note on Monday, January 13th. Four research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat.com, Halozyme Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $60.89.

Insider Activity

In other news, Director Jeffrey William Henderson sold 10,000 shares of the business’s stock in a transaction on Monday, January 6th. The shares were sold at an average price of $50.01, for a total transaction of $500,100.00. Following the sale, the director now directly owns 43,611 shares of the company’s stock, valued at $2,180,986.11. The trade was a 18.65 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 2.70% of the company’s stock.

Hedge Funds Weigh In On Halozyme Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in HALO. RPg Family Wealth Advisory LLC purchased a new position in Halozyme Therapeutics in the 3rd quarter valued at $1,886,000. Segall Bryant & Hamill LLC lifted its stake in shares of Halozyme Therapeutics by 16.3% in the third quarter. Segall Bryant & Hamill LLC now owns 355,176 shares of the biopharmaceutical company’s stock worth $20,330,000 after buying an additional 49,856 shares in the last quarter. Retirement Systems of Alabama boosted its position in Halozyme Therapeutics by 23.5% during the third quarter. Retirement Systems of Alabama now owns 389,268 shares of the biopharmaceutical company’s stock worth $22,282,000 after acquiring an additional 74,173 shares during the last quarter. Creative Planning grew its stake in Halozyme Therapeutics by 43.2% during the 2nd quarter. Creative Planning now owns 37,291 shares of the biopharmaceutical company’s stock valued at $1,953,000 after acquiring an additional 11,249 shares in the last quarter. Finally, South Street Advisors LLC acquired a new stake in Halozyme Therapeutics in the 3rd quarter valued at about $9,812,000. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.